(Z)-1-methyl-5-((2-morpholinopyrimidin-4-yl)methylene)imidazolidine-2,4-dione | 1332366-59-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并嘧啶类
• 英文名称: (Z)-1-methyl-5-((2-morpholinopyrimidin-4-yl)methylene)imidazolidine-2,4-dione
• 英文别名: (5Z)-1-methyl-5-[(2-morpholin-4-ylpyrimidin-4-yl)methylidene]imidazolidine-2,4-dione
• CAS: 1332366-59-2
• 化学式: C₁₃H₁₅N₅O₃
• 分子量: 289.294
• InChiKey: QZNPIPDWHZXDML-NTMALXAHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.3
• 重原子数：
  21
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  87.7
• 氢给体数：
  1
• 氢受体数：
  6

文献信息

• Imidazole-2,4-Dione Inhibitors of Casein Kinase 1
  申请人：Baldino Carmen M.

  公开号：US20120316155A1

  公开（公告）日：2012-12-13

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway.

  本发明涉及一些化合物，其中包括这些化合物的药物组合物，以及这些化合物和组合物作为酪氨酸激酶1（例如CK1γ）、TGFβ途径和/或Wnt途径的调节剂的用途。本发明还涉及用于治疗或预防一系列治疗适应症的用途，这些治疗适应症至少部分归因于酪氨酸激酶1（例如CK1γ）、TGFβ途径和/或Wnt途径的异常生理活动。
• PHOSPHOLIPID-DETERGENT CONJUGATES AND USES THEREOF
  申请人：Lebeau Luc

  公开号：US20140243391A1

  公开（公告）日：2014-08-28

  The invention relates to novel compounds, in particular novel O-substituted phospholipids that are useful for the in vitro and in vivo delivery of drugs as well as nucleic acids into cells. The invention also relates to pharmaceutical compositions and supramolecular complexes comprising said compounds and the use of these compounds in therapeutic treatment, in particular in gene therapy.

  本发明涉及新型化合物，特别是新型O取代磷脂，可用于体外和体内将药物以及核酸输送到细胞中。本发明还涉及包含所述化合物的药物组合物和超分子复合物，以及这些化合物在治疗中的使用，特别是在基因治疗中的使用。
• US9073903B2
  申请人：——

  公开号：US9073903B2

  公开（公告）日：2015-07-07
• [EN] IMIDAZOLE-2, 4-DIONE INHIBITORS OF CASEIN KINASE 1<br/>[FR] INHIBITEURS IMIDAZOLE-2, 4-DIONE DE LA CASÉINE KINASE 1
  申请人：JASCO PHARMACEUTICALS LLC

  公开号：WO2011103289A2

  公开（公告）日：2011-08-25

  Disclosed are compounds, pharmaceutical compositions containing those compounds, and uses of the compounds and compositions as modulators of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway. Uses are also disclosed for the treatment or prevention of a range of therapeutic indications due at least in part to aberrant physiological activity of casein kinase 1 (e.g., CK1γ), the TGFβ pathway and/or the Wnt pathway.